Cargando…

Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations

Cytology from gastrointestinal (GI) cancers is frequently obtained from ascites and peritoneal washing fluids. Examination of ascites and peritoneal washing fluids from patients with GI cancers can help in the tumor staging and prognosis. Tumor-derived DNA in these cytology samples can be a target f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Go Eun, Kim, Seok-Hwan, Choi, Min Kyung, Kim, Jin-Man, Yeo, Min-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319747/
https://www.ncbi.nlm.nih.gov/pubmed/34336700
http://dx.doi.org/10.3389/fonc.2021.712754
_version_ 1783730516777762816
author Bae, Go Eun
Kim, Seok-Hwan
Choi, Min Kyung
Kim, Jin-Man
Yeo, Min-Kyung
author_facet Bae, Go Eun
Kim, Seok-Hwan
Choi, Min Kyung
Kim, Jin-Man
Yeo, Min-Kyung
author_sort Bae, Go Eun
collection PubMed
description Cytology from gastrointestinal (GI) cancers is frequently obtained from ascites and peritoneal washing fluids. Examination of ascites and peritoneal washing fluids from patients with GI cancers can help in the tumor staging and prognosis. Tumor-derived DNA in these cytology samples can be a target for next generation sequencing (NGS). Targeted NGS was evaluated in ascites and peritoneal washing samples obtained from 33 patients with GI cancers. These sequences were compared with those from tumor tissue samples, and correlated with cytopathologic findings of the ascites and peritoneal fluid samples. The correlation between fluid and tissue genotyping results was 25%, with a sensitivity of 21.43%. The volume of tumor contained within the fluid samples was low, ranging from ~0 to 10%. Importantly, the sensitivity of detection of somatic mutations in the fluid samples could be increased to 69.2% by assessing samples containing >2% tumor volume. Evaluation of cells from ascitic fluid showed the presence of KRAS, TP53, and CDH1 mutations in 33, 13, and 7%, respectively, of patients with pancreatic cancer, and the presence of KRAS, TP53, and APC mutations in 25, 12, and 13%, respectively, of patients with gastric cancer. Ascites of one of the latter patients acquired KRAS mutation, which was a novel mutation during metastasis. Targeted NGS of ascites and peritoneal washing fluid have clinical implications, as well as limitations, in patients with GI cancers. NGS-based cytology examination may expand cytomolecular practices in GI cancer patients.
format Online
Article
Text
id pubmed-8319747
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83197472021-07-30 Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations Bae, Go Eun Kim, Seok-Hwan Choi, Min Kyung Kim, Jin-Man Yeo, Min-Kyung Front Oncol Oncology Cytology from gastrointestinal (GI) cancers is frequently obtained from ascites and peritoneal washing fluids. Examination of ascites and peritoneal washing fluids from patients with GI cancers can help in the tumor staging and prognosis. Tumor-derived DNA in these cytology samples can be a target for next generation sequencing (NGS). Targeted NGS was evaluated in ascites and peritoneal washing samples obtained from 33 patients with GI cancers. These sequences were compared with those from tumor tissue samples, and correlated with cytopathologic findings of the ascites and peritoneal fluid samples. The correlation between fluid and tissue genotyping results was 25%, with a sensitivity of 21.43%. The volume of tumor contained within the fluid samples was low, ranging from ~0 to 10%. Importantly, the sensitivity of detection of somatic mutations in the fluid samples could be increased to 69.2% by assessing samples containing >2% tumor volume. Evaluation of cells from ascitic fluid showed the presence of KRAS, TP53, and CDH1 mutations in 33, 13, and 7%, respectively, of patients with pancreatic cancer, and the presence of KRAS, TP53, and APC mutations in 25, 12, and 13%, respectively, of patients with gastric cancer. Ascites of one of the latter patients acquired KRAS mutation, which was a novel mutation during metastasis. Targeted NGS of ascites and peritoneal washing fluid have clinical implications, as well as limitations, in patients with GI cancers. NGS-based cytology examination may expand cytomolecular practices in GI cancer patients. Frontiers Media S.A. 2021-07-15 /pmc/articles/PMC8319747/ /pubmed/34336700 http://dx.doi.org/10.3389/fonc.2021.712754 Text en Copyright © 2021 Bae, Kim, Choi, Kim and Yeo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bae, Go Eun
Kim, Seok-Hwan
Choi, Min Kyung
Kim, Jin-Man
Yeo, Min-Kyung
Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title_full Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title_fullStr Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title_full_unstemmed Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title_short Targeted Sequencing of Ascites and Peritoneal Washing Fluid of Patients With Gastrointestinal Cancers and Their Clinical Applications and Limitations
title_sort targeted sequencing of ascites and peritoneal washing fluid of patients with gastrointestinal cancers and their clinical applications and limitations
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319747/
https://www.ncbi.nlm.nih.gov/pubmed/34336700
http://dx.doi.org/10.3389/fonc.2021.712754
work_keys_str_mv AT baegoeun targetedsequencingofascitesandperitonealwashingfluidofpatientswithgastrointestinalcancersandtheirclinicalapplicationsandlimitations
AT kimseokhwan targetedsequencingofascitesandperitonealwashingfluidofpatientswithgastrointestinalcancersandtheirclinicalapplicationsandlimitations
AT choiminkyung targetedsequencingofascitesandperitonealwashingfluidofpatientswithgastrointestinalcancersandtheirclinicalapplicationsandlimitations
AT kimjinman targetedsequencingofascitesandperitonealwashingfluidofpatientswithgastrointestinalcancersandtheirclinicalapplicationsandlimitations
AT yeominkyung targetedsequencingofascitesandperitonealwashingfluidofpatientswithgastrointestinalcancersandtheirclinicalapplicationsandlimitations